Skip to main content

Advertisement

SpringerLink
Log in

Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists

  • Commentary
  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Sudden cardiac death (SCD) related to ventricular arrhythmias is the most disastrous consequence of hypertrophic cardiomyopathy (HCM). Hence, clinicians seek to identify the highest risk patients that have the greatest potential to benefit from an implantable cardioverter-defibrillator (ICD) for primary prevention; nonetheless, this is where controversies begin as the 2011 American College of Cardiology Foundation/American Heart Association and the 2014 European Society of Cardiology guidelines have significant discrepancies. These guidelines propose clinically and statistically oriented algorithms, respectively, for SCD risk stratification of patients with HCM and recommendation to implantation of primary prevention ICD. The differences between these guidelines have resulted in confusion among care practitioners and patients alike. In this communication, we tried to criticize the statistical viewpoint in terms of clinical outcomes and suggest the more beneficial model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2011;142(6):e153–203. https://doi.org/10.1016/j.jtcvs.2011.10.020.

    Article  PubMed  Google Scholar 

  2. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. https://doi.org/10.1093/eurheartj/ehu284.

    Article  PubMed  Google Scholar 

  3. Ruiz-Salas A, Garcia-Pinilla JM, Cabrera-Bueno F, Fernandez-Pastor J, Pena-Hernandez J, Medina-Palomo C, et al. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator. Europace. 2016;18(5):773–7. https://doi.org/10.1093/europace/euv079.

    Article  PubMed  Google Scholar 

  4. Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, Ten Cate FJ, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829–35. https://doi.org/10.1161/CIRCEP.114.002553.

    Article  PubMed  Google Scholar 

  5. Fernandez A, Quiroga A, Ochoa JP, Mysuta M, Casabe JH, Biagetti M, et al. Validation of the 2014 European Society of Cardiology sudden cardiac death risk prediction model in hypertrophic cardiomyopathy in a reference center in South America. Am J Cardiol. 2016;118(1):121–6. https://doi.org/10.1016/j.amjcard.2016.04.021.

    Article  PubMed  Google Scholar 

  6. O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International external validation study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137(10):1015–23. https://doi.org/10.1161/circulationaha.117.030437.

    Article  PubMed  Google Scholar 

  7. Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116(5):757–64. https://doi.org/10.1016/j.amjcard.2015.05.047.

    Article  PubMed  Google Scholar 

  8. Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, et al. Enhanced American College of Cardiology/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2019;4:644–57. https://doi.org/10.1001/jamacardio.2019.1391.

    Article  PubMed  Google Scholar 

  9. Ho CY, Link MS. Predicting the future in hypertrophic cardiomyopathy. Circulation. 2018;137(10):1024–6.

    Article  Google Scholar 

  10. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidimiology. 2010;21(1):128–38. https://doi.org/10.1097/EDE.0b013e3181c30fb2.

    Article  Google Scholar 

  11. Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm. 2016;13(5):1155–65. https://doi.org/10.1016/j.hrthm.2015.12.048.

    Article  PubMed  Google Scholar 

  12. Wang N, Xie A, Tjahjono R, Tian DH, Phan S, Yan TD, et al. Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications. Ann Cardiothorac Surg. 2017;6(4):298–306. https://doi.org/10.21037/acs.2017.07.05.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, et al. Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol. 2018;11(4):e005820.

    Article  Google Scholar 

  14. Steyerberg EW, Calster BV, Pencina MJ. Performance measures for prediction models and markers: evaluation of predictions and classifications. Rev Esp Cardiol. 2011;64(9):788–94. https://doi.org/10.1016/j.rec.2011.05.004.

    Article  PubMed  Google Scholar 

  15. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72. https://doi.org/10.1002/sim.2929.

    Article  Google Scholar 

  16. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565–74. https://doi.org/10.1177/0272989X06295361.

    Article  Google Scholar 

  17. You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. 2007;154(5):899–907. https://doi.org/10.1016/j.ahj.2007.06.026.

    Article  PubMed  Google Scholar 

  18. Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005;10(4 Suppl):67–83. https://doi.org/10.1111/j.1542-474X.2005.00070.x.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358(9286):993–8. https://doi.org/10.1016/s0140-6736(01)06107-4.

    Article  CAS  PubMed  Google Scholar 

  20. McKeown PP, Muir AR. Risk assessment in hypertrophic cardiomyopathy: contemporary guidelines hampered by insufficient evidence. Heart. 2013;99(8):511–3. https://doi.org/10.1136/heartjnl-2012-303363.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Klopotowski M, Kukula K, Malek LA, Spiewak M, Polanska-Skrzypczyk M, Jamiolkowski J, et al. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiol. 2016;68(1):49–56. https://doi.org/10.1016/j.jjcc.2015.07.020.

    Article  PubMed  Google Scholar 

  22. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484–95. https://doi.org/10.1161/circulationaha.113.007094.

    Article  PubMed  Google Scholar 

  23. Fluechter S, Kuschyk J, Wolpert C, Doesch C, Veltmann C, Haghi D, et al. Extent of late gadolinium enhancement detected by cardiovascular magnetic resonance correlates with the inducibility of ventricular tachyarrhythmia in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2010;12:30. https://doi.org/10.1186/1532-429x-12-30.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Prinz C, Schwarz M, Ilic I, Laser KT, Lehmann R, Prinz EM, et al. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can J Cardiol. 2013;29(3):358–63. https://doi.org/10.1016/j.cjca.2012.05.004.

    Article  PubMed  Google Scholar 

  25. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3(1):51–8. https://doi.org/10.1161/circheartfailure.109.854026.

    Article  PubMed  Google Scholar 

  26. Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart. 2015;101(17):1406–11. https://doi.org/10.1136/heartjnl-2015-307682.

    Article  CAS  PubMed  Google Scholar 

  27. Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. J Am Coll Cardiol Img. 2016;9(12):1392–402. https://doi.org/10.1016/j.jcmg.2016.02.031.

    Article  Google Scholar 

  28. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118(15):1541–9.

    Article  Google Scholar 

  29. Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management. J Am Coll Cardiol. 2017;69(7):761–73. https://doi.org/10.1016/j.jacc.2016.11.063.

    Article  PubMed  Google Scholar 

  30. Rowin EJ, Maron BJ, Chokshi A, Maron MS. Left ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age. Pacing Clin Electrophysiol. 2018;41:1031–3. https://doi.org/10.1111/pace.13413.

    Article  Google Scholar 

  31. Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, et al. Impact of advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;121(8):986–96. https://doi.org/10.1016/j.amjcard.2017.12.044.

    Article  PubMed  Google Scholar 

  32. Vriesendorp PA, Schinkel AF, Van Cleemput J, Willems R, Jordaens LJ, Theuns DA, et al. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. Am Heart J. 2013;166(3):496–502. https://doi.org/10.1016/j.ahj.2013.06.009.

    Article  PubMed  Google Scholar 

  33. Girolami F, Ho CY, Semsarian C, Baldi M, Will ML, Baldini K, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol. 2010;55(14):1444–53. https://doi.org/10.1016/j.jacc.2009.11.062.

    Article  CAS  PubMed  Google Scholar 

  34. Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation. Circulation. 2014;130(18):1617–24.

    Article  Google Scholar 

  35. Cuoco FA, Spencer WH, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;52(21):1718–23. https://doi.org/10.1016/j.jacc.2008.07.061.

    Article  PubMed  Google Scholar 

  36. Jensen MK, Prinz C, Horstkotte D, van Buuren F, Bitter T, Faber L, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013;99(14):1012–7. https://doi.org/10.1136/heartjnl-2012-303339.

    Article  PubMed  Google Scholar 

  37. Veselka J, Tomasov P, Zemanek D. Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol. 2011;27(6):763–7. https://doi.org/10.1016/j.cjca.2011.09.001.

    Article  CAS  PubMed  Google Scholar 

  38. Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AFL, Willems R, ten Cate FJ, et al. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC: Heart Failure. 2014;2(6):630–6. https://doi.org/10.1016/j.jchf.2014.06.012.

    Article  PubMed  Google Scholar 

  39. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail. 2010;3(3):362–9. https://doi.org/10.1161/circheartfailure.109.862359.

    Article  PubMed  Google Scholar 

  40. Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2009;104(1):128–32. https://doi.org/10.1016/j.amjcard.2009.02.056.

    Article  PubMed  Google Scholar 

  41. Saumarez RC, Pytkowski M, Sterlinski M, Bourke JP, Clague JR, Cobbe SM, et al. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J. 2008;29(13):1653–61. https://doi.org/10.1093/eurheartj/ehn111.

    Article  PubMed  Google Scholar 

  42. Maron BJ, Rowin EJ, Casey SA, Lesser JR, Garberich RF, McGriff DM, et al. Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies. Circulation. 2016;133(1):62–73. https://doi.org/10.1161/circulationaha.115.017633.

    Article  PubMed  Google Scholar 

  43. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61(14):1527–35. https://doi.org/10.1016/j.jacc.2013.01.037.

    Article  PubMed  Google Scholar 

  44. Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113(9):1550–5. https://doi.org/10.1016/j.amjcard.2014.01.435.

    Article  PubMed  Google Scholar 

  45. Maron BJ, Maron MS, Lesser JR, Hauser RG, Haas TS, Harrigan CJ, et al. Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. Am J Cardiol. 2008;101(4):544–7. https://doi.org/10.1016/j.amjcard.2007.09.101.

    Article  PubMed  Google Scholar 

  46. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, et al. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol. 2015;65(18):1915–28. https://doi.org/10.1016/j.jacc.2015.02.061.

    Article  PubMed  Google Scholar 

  47. Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013;127(5):585–93. https://doi.org/10.1161/circulationaha.112.136085.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Arya Aminorroaya

  2. Cardiac Primary Prevention Research Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran

    Ali Vasheghani-Farahani, Farzad Masoudkabir & Pegah Roayaei

  3. Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

    Farzad Masoudkabir

Authors
  1. Arya Aminorroaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ali Vasheghani-Farahani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Farzad Masoudkabir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pegah Roayaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farzad Masoudkabir.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aminorroaya, A., Vasheghani-Farahani, A., Masoudkabir, F. et al. Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists. J Interv Card Electrophysiol 60, 1–7 (2021). https://doi.org/10.1007/s10840-020-00837-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-020-00837-4

Keywords

Search

Navigation